Intellia Therapeutics (NTLA) Long-Term Investments (2019 - 2026)

Intellia Therapeutics (NTLA) has reported Long-Term Investments for 7 consecutive years, with $10.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments rose 347.24% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at $10.1 million (up 347.24% YoY), while the FY2025 annual figure was $11.4 million, down 95.61% from the prior year.
• Long-Term Investments retreated to $10.1 million in Q1 2026 per NTLA's latest filing, from $11.4 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $260.2 million in Q4 2024 and bottomed at $2.3 million in Q1 2025.
• Historically, Long-Term Investments has averaged $66.5 million across 5 years, with a median of $32.6 million in 2022.
• Annual changes were most pronounced in 2024 — Long-Term Investments soared 2502.15% — and 2025, when it slumped 98.6%.
• Intellia Therapeutics' Long-Term Investments stood at $32.5 million in 2022, then slumped by 69.19% to $10.0 million in 2023, then jumped by 2502.15% to $260.2 million in 2024, then sank by 95.61% to $11.4 million in 2025, then retreated by 11.33% to $10.1 million in 2026.
• Business Quant data shows NTLA's Long-Term Investments at $10.1 million in Q1 2026, $11.4 million in Q4 2025, and $22.5 million in Q3 2025.